Buscar
Mostrando ítems 1-10 de 27
Ocular toxicity of intravitreous adalimumab (Humira) in the rabbit
(SPRINGER, 2008)
Purpose To evaluate the ocular toxicity of escalating doses of intravitreous adalimumab (Humira) in the rabbit eye. Methods Twelve New Zealand albino rabbits received unilateral intravitreous injections of 0.1 ml of ...
Adalimumab for maintenance therapy for one year in Crohn's disease: results of a Latin American single-center observational study
(2014)
Adalimumab is a fully-human antibody that inhibits TNF alpha, with a significant efficacy for long-term maintenance of remission. Studies with this agent in Latin American Crohn's disease patients are scarce. The objective ...
Tratamiento de Artritis reumatoide con antagonistas del factor de necrosis tumoral alfa y su asociación con el desarrollo de melanoma cutáneo: revisión sistemática de la literatura y meta-análisis.
(Universidad del RosarioFacultad de medicina, 2015)
Introduction: Treatment with antagonists of the tumor necrosis factor alpha (anti-
TNF) has impacted the prognosis and quality of life of patients with rheumatoid arthritis
(RA) positively, however, there may be an ...
Adesão e persistência ao tratamento com agentes biológicos fornecidos pelo Sistema Único de Saúde para doenças reumáticas em Minas Gerais.
(Universidade Federal de Minas GeraisBrasilFARMACIA - FACULDADE DE FARMACIAPrograma de Pós-Graduação em Medicamentos e Assistencia FarmaceuticaUFMG, 2013-04-28)
The aim of this study was to measure nonadherence and nonpersistence to biological therapy in patients with rheumatic diseases treated in the National Health System in Minas Gerais State, as well as factors associated with ...
Viés de publicação em ensaios clínicos sobre anticorpos monoclonais e repercussão jurídica do direito fundamental à saúde baseada em evidências
(Universidade Federal de São Paulo (UNIFESP), 2014-12-31)
Aims: We aimed to assess the proportion of publication and reporting of results of clinical trials on monoclonal antibodies adalimumab, bevacizumab, rituximab, trastuzumab and infliximab registered at ClinicalTrials.gov. ...